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Background: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive
stimulation technique which has a treatment potential for alcohol use disorder.
Intermittent theta burst stimulation (iTBS) is a new rTMS technique which is shorter in
duration and thus with better tolerability and shows similar efficacy as rTMS for the
treatment of depression. The effect of iTBS on reducing craving in alcohol use disorder
patients requires further investigation.
Methods: A randomized, controlled, single-blind, multicenter study with 60 alcohol use
disorder patients randomized (2:1) to the iTBS group or the control group (sham iTBS).
The stimulation target will be identical in the left dorsolateral prefrontal cortex (DLPFC).
Baseline evaluations will be occurred before the intervention, after the intervention
immediately, and 1 and 3 months after the intervention. The primary outcome of the
study will be decrease of visual analogue scale (VAS) scores from baseline to the end
of treatment.
Discussion: This study is a randomized controlled trial to investigate the efficacy of left
DLPFC iTBS in a population of alcohol use disorder patients, compared with sham iTBS. If
it is effective for alcohol use disorder, it may provide a potential treatment which is
tolerable, accessible, and clinical useful.
Cinical Trial Registration: This study is registered in the ClinicalTrials with trial number
NCT03932149. Registered 17 April 2019.
Keywords: alcohol use disorder, iTBS, craving, randomized controlled trial, non-invasive brain stimulationAbbreviations: rTMS, Repetitive transcranial magnetic stimulation; cTBS, Continuous theta burst stimulation; iTBS,
Intermittent theta burst stimulation; mPFC, medial prefrontal cortex; DLPFC, dorsolateral prefrontal cortex; DD, delay
discounting; VAS, Visual analogue scale; PACS, Penn alcohol craving scale; CIWA-Ar, Clinical institute withdrawal
assessment of alcohol scale, revised; BDI, Beck depression inventory; BAI, Beck anxiety inventory; BIS, Barratt
impulsiveness scale; SST, Stop signal task; SSRT, Stop signal reaction time; RMT, Resting motor threshold.
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Alcohol dependence or alcohol use disorder (AUD) is a major
international public health issue and a chronic disease with high
relapse rates (1). Marked medical and psychiatric comorbidity
and high numbers of premature deaths result from direct and
indirect causes of excessive alcohol use (2). The disorder is
associated with key societal impact goals influencing health
related targets relevant to the Sustainable Development Goals
(SDGs) of maternal and child health, mental health, injuries, and
poisonings. Worldwide alcohol abuse was responsible for 3
million deaths (5.3% of all deaths) in 2016 and 132.6 million
disability-adjusted life years (3). Critically however, the
treatment of alcohol addiction is currently limited to acute
withdrawal symptoms, but lacks effective interventions to
reduce craving and prevent relapse, which are clinically the
most relevant targets for the treatment of substance
dependence. According to previous studies, non-conscious
appetitive reactions occur when patients are exposed to
alcohol-related cues and these reactions might explain why
AUD patients relapse (4, 5). Furthermore, brain activity in
reward-related areas in response to alcohol-related cues is
positively related to the amount of post-relapse alcohol
consumption (6). Thus, one way to effectively treat AUD may
be through a targeted neurostimulation. An increasing number
of studies have suggested a potential role for non-invasive
neuromodulation as a means to target AUD (7, 8).
Repetitive transcranial magnetic stimulation (rTMS) is a non-
invasive, cortical stimulation technique. An alternating electric
current is applied from a coil which produces a magnetic field
that depending on the frequency, can inhibit or activate cortical
neurons both locally at the site of the coil and also have more
distal network effects. The current results in high intensity
magnetic pulses that pass through the skull and result in an
electric current in the neural tissue, which can change cortical
activity (7, 9). rTMS has been shown to be effective in large
randomized controlled trial studies in a range of neuropsychiatric
diseases including depression and obsessive-compulsive disorder
(10, 11). With respect to disorders of addiction, a meta‐analysis
revealed a significant anti‐craving effect of excitatory rTMS of the
left dorsolateral prefrontal cortex (DLPFC) in patients with
substance dependence (12). In AUD specifically, one study
suggested that high-frequency rTMS on either right or left
DLPFC significantly reduce craving scores in patients (13). In
contrast, another study showed that a single rTMS stimulation
session had no significant effects on alcohol craving in alcohol
dependent patients emphasizing the potential need for repeated
sessions (14). Several studies have reported the potential of rTMS
to reduce craving in people with alcohol dependence, but
multiple different parameters and protocols were reported with
limited consistency (13–18).
Theta burst stimulation (TBS) is a rTMS technique that
displays faster and more robust action compared to
conventional rTMS protocols (19), and has excellent
tolerability (20) and safety (21). intermittent theta burst
stimulation (iTBS) and continuous theta burst stimulation
(cTBS) are two different methods with facilitating andFrontiers in Psychiatry | www.frontiersin.org 2inhibitory effects, respectively (22). A randomized, multicenter,
non-inferiority trial to compare iTBS with 10 Hz rTMS in
patients with treatment-resistant depression targeting the left
DLPFC demonstrated that iTBS was non-inferior to
conventional 10 Hz rTMS in the treatment of depression (23).
An increasing number of studies have focused on TBS in the field
of addiction. One study demonstrated that both medial
prefrontal cortex (mPFC) rTMS and right DLPFC cTBS
reduced gambling reinforcement in pathological gamblers (24).
A recent pilot study showed that 4 sessions of iTBS added to
cognitive-behavioral therapy (CBT) improved nicotine
abstinence. The study provided evidence for a potential effect
of additional iTBS on nicotine dependence and for lasting effects,
enhanced abstinence rates for up to three months (25). To data,
no reported studies investigating the efficacy of left DLPFC iTBS
in reducing craving in AUD patients.SPECIFIC AIMS
The aim of this double-blind randomized controlled trial is to
investigate the efficacy of left DLPFC iTBS in a population of
alcohol use disorder patients, compared with sham iTBS. The
primary outcome is effect on craving and secondary outcomes
are longitudinal outcomes on amount of alcohol and
relapse rates.METHODS/DESIGN
Study Design
This is a randomized, controlled, double-blind, multicenter study
carried out at Shanghai Mental Health Center and other
hospitals in China. The patients will be randomly (2:1)
assigned to the iTBS group or the control group (sham iTBS).
The stimulation target is identical in the left DLPFC. A series of
evaluations will be taken before the intervention, after the
intervention immediately, and 1 and 3 months after the
intervention. All participants provide written, informed consent.
Ethical Considerations
This study is registered in ClinicalTrials (trial number
NCT03932149). The ethics approval is received by Institutional
Review Board of Shanghai Mental Health Center (SMHC-IRB)
and the number is 2019ky-77. Prior to screening, all participants
will have written informed consent.
Inclusion and Exclusion Criteria
Inclusion criteria are (1) a DSM-5 diagnosis of alcohol use
disorder, (2) age between 18 and 65, (3) clinical institute
withdrawal assessment of alcohol scale, revised (CIWA-Ar)
score of <10, (4) able to complete follow-up visits. Exclusion
criteria are (1) severe cognitive impairment, (2) current DSM-5
diagnosis of schizophrenia or another psychotic disorder, (3)
severe organic diseases, (4) rTMS contraindications (such as a
history of epileptic seizures, metal implants near the head).March 2020 | Volume 11 | Article 210
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Before recruitment begins at each site, a fixed-size randomization
table will be generated using a computer-based algorithm which
generates a random replacement block. Staff outside the research
team will use the randomization table to insert the participant-
specific randomized identification numbers and treatment
assignment codes into opaque sealed envelopes. After
collecting patient details and baseline assessments, the
researchers will assign randomized identification numbers to
participants to identify treatment assignments. The staff
assessing treatment outcomes are different from the staff
administering the TMS, so they are also blinded to treatment
conditions. Although the assignments are randomized and
participants are blinded to treatment arm, they will be
instructed to not discuss their treatment assignments with staff
or other participants. After the intervention, the participants will
complete a paper and pen assessment wherein individuals state if
they think they received real or sham, how confident they are,
and to write a brief description evaluating the integrity of the
blind. Participants will also complete a paper and pen assessment
using a visual analogue scale to assess pain to evaluate the
integrity of the sham stimulation.Study Process
Patients will be recruited and screened for inclusion and
exclusion criteria. If a patient passes the screening, he/she will
be recruited in the study and sign the informed consent. All the
participants who complete the baseline assessments will be
randomly assigned to two groups.
Both groups will receive 10 sessions (twice daily on weekdays)
intervention (experiment group receives active stimulations;
control group receives sham stimulations) and finish follow-up
assessments after the last session, and three months after the last
session. Prior to the study, each participant will be interviewed to
assess which type of alcohol they commonly misuse and the glass
type they use. Before each session, the participants will be
exposed to a variety of alcohol types (wine, liquor) and glass
types. They will be able to choose their preferred alcohol variety
and touch and/or smell for one minute. A visual analogue scale
(VAS) will be used to rate craving. We will use the side effects
scale to do the assessment after the intervention. If there are
acute and severe side effects, we will stop the intervention, report
to IRB office, and provide appropriate treatment to patients
based on the contents of inform contents. ”Green channel” for
patients has been set up, provide first aid to patient if necessary.
The procedure of the study is shown in the flow chart (Figure 1).Assessments
During the baseline assessments, the sociodemographic and
assessment for alcohol use will be documented. Before the
intervention, after the last session, and 1 and 3 months after
the last session, the following scales are evaluated:
The VAS is a rating scale with few constraints. The VAS
consists of a 10-centimeter line on which the respondent marks
the degree of their craving. The respondent have great freedomFrontiers in Psychiatry | www.frontiersin.org 3to mark anywhere on the line so that it will show the exact
intensity of their craving and their response style (26).
Obsessive compulsive drinking scale (OCDS), a 14-item quick
and reliable self-rating instrument provides a total and two
subscale scores that measures urge and compulsion aspects of
alcohol “craving” (27).
Clinical institute withdrawal assessment of alcohol scale,
revised (CIWA-Ar) is a shortened scale with 10 items to
measure the severity of alcohol withdrawal syndrome. The
shortened version increases efficiency with similar validity and
reliability in clinical care and clinical trials on alcohol
withdrawal (28).
Beck depression inventory (BDI) is a self-report inventory
with 21 items to evaluate the severity of depression (29).
Beck anxiety inventory (BAI) is a self-report inventory with
21 items to evaluate the severity of anxiety (30).
Barratt impulsiveness scale (BIS) is a 30-item self-report scale
to measure impulsiveness and it is used widely (31).
In addition to the scales, the following behavioural tasks will
be conducted:
Stop signal task (SST) is a behavioral task to measure response
inhibition (impulse control). The participant is told to select the
left-hand button when they see a left-pointing arrow and select
the right-hand button when they see a right-pointing arrow, but
if they hear an auditory signal (a beep), they should withhold
their response and not select a button. The outcome measure is
stop signal reaction time (SSRT).
Cogstate computerized cognitive assessment tool (CCAT),
include international shopping list task (ISLT), detection task
(DET), identification task (IDN), two back task (TWOB),FIGURE 1 | Flow chart of the study.March 2020 | Volume 11 | Article 210
Yuan et al. iTBS in AUD Patientscontinuous paired associate learning task (CPAL), groton maze
learning test (GML), and social-emotional cognition task (SEC)
to evaluate cognitive functions.Interventions
The TBS will be administered using a MagVenture MagPro R30
machine, connected to a figure-of-eight-formed 90 mm coil held
tangentially to the skull. Each participant's resting motor
threshold (RMT) is defined as the minimum intensity that
produces minimal motor-evoked potentials (MEPs). It requires
peak-to-peak amplitude of about 50-mV in at least five of 10
stimulations. The target is left DLPFC and the iTBS protocol is as
follows: 80% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2 s
on and 8 s off; 600 pulses a session lasting a total of 3 min. The
treatment comprises 10 sessions in total, which consist of twice-
daily sessions (one time in the morning and one time in the
afternoon, 10 sessions a week). The sham stimulations use the
same protocol with the coil rotated 180° away from the skull.
Patients in sham group could hear the sound of the coil, but the
electric field could not induce neuronal activation in their brain.
During the iTBS sessions, the participants will be told to keep
their eyes open and to relax. After each session, the participants
will report adverse events.
Primary Outcome Measures
The primary outcome of the study will be the decrease of VAS
scores from baseline to the end of treatment.
Secondary Outcome Measures
The secondary outcome measures of the study will be: the
abstinence rate after the treatment, defined as the number of
abstinent days in the three months after the last simulation
session; the decrease of PSQI, BDI, BAI, BIS scores; the decrease
of SSRT; and the increase of Cogstate tasks scores.
Statistical Analyses
To our knowledge no studies have investigated the effect of left
DLPFC iTBS on the craving of alcohol use disorder patients.
Therefore, to estimate the sample size we would need, we
estimate the sample size referring to a previous study with a
similar design, which investigated the efficacy of repetitive
transcranial magnetic stimulation in alcohol dependence (18).
According to that previous study, we hypothesized that we need
at least a similar number of participants (30 participants in the
active experiment group). Because we need to conduct three
months follow-up assessments, considering a drop-out
percentage of 10% (32), the current study will include 38–40
patients in the active stimulation group, resulting in a total of
approximately 60 participants.
The data will be analyzed using the Statistical Package for
Social Sciences (SPSS). The alpha level will be set at P < 0.05
(two-tailed) for statistical hypothesis. Descriptive analyses will be
conducted to determine whether randomization procedure
resulted in two groups having no differences in distribution of
demographic factors. Appropriate parametric and non-Frontiers in Psychiatry | www.frontiersin.org 4parametric statistical tests will be conducted to analyze
descriptive statistics. Multiple comparison corrections will be
conducted if necessary. To compare two groups at post-
treatment and follow-up assessments, mixed models will be
applied and the analysis of covariance (ANCOVA) will be
applied to control the effects of covariates (e.g., age, alcohol
use history). If the data are not normally distributed,
nonparametric tests will be applied.DISCUSSION
Currently the treatment of alcohol use disorder is limited to
psychosocial and pharmacological treatment. However, these
treatments still have greater than 50% relapses of all treated
patients within one year suggesting only a moderate effect (33).
With the development of rTMS, the treatment of alcohol use
disorder has new potential. iTBS is a newer form of rTMS which
has been shown to improve the induction of synaptic long-term
potentiation (34). The effect is similar to high frequency rTMS but
in a shorter time. This paper presents a double blind randomized
clinical trial protocol investigating the effect of left DLPFC iTBS on
treating alcohol use disorder.
This study requires a three months follow-up assessment,
which may be the challenge of the study. It may be difficult for
alcohol dependent individuals to complete the whole
procedure, so the rate of withdrawal may also higher (35).
As we may not obtain a sufficient sample size to adequately
assess the longitudinal abstinence rate after the treatment; this
outcome measure is the secondary outcome. According to
previous studies, we assume the sample size is reasonable. If
the dropout rate is too high to meet the requirements of the
current study, we will report to IRB and recruit participants
according to the protocol requirements.
The limitation of this study is lack of objective measures to assess
the alcohol use at the follow up phase, since alcohol metabolizes so
fast. In the next step, we hope to find appropriate measures to
evaluate the alcohol use accurately.
To our knowledge, this is the first randomized, multicenter
trial to investigate the effect of left DLPFC iTBS on treating
alcohol use disorder. If we show that left DLPFC iTBS is effective
for alcohol use disorder, it may provide a potential treatment
which is accessible, well-tolerated, and clinically useful.
Suspension of Clinical Trial Standards
If the patient is unable to complete the relevant examination,
assessment, or cannot complete the follow-up at the specified
time within the agreed time, or initiate a suspension study, the
clinical trial will be suspended.
Adverse Event Report
Adverse events that occurred during the study will be notified to
the principal investigator as soon as possible, and the primary
investigator and the research doctor will jointly determine the
treatment plan. Serious adverse events will be reported to the
main investigator, ethics committee, and relevant administrative
departments within 24 h and processed in a timely manner.March 2020 | Volume 11 | Article 210
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The case report forms completed by the study doctor, the results of
the scale assessment and all test results will be kept in the
researcher's computer and office in paper or electronic form. This
study has a dedicated inspector responsible for the data
administrator, and a regular meeting of the research group (once
a month) to feed back the research progress and related issues.
All evaluators and data analysts in this study have received
relevant professional training to ensure the quality of the
enrollment and the quality of post-processing.ETHICS STATEMENT
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